AIMS: Single dose pharmacokinetics and safety of irbesartan, an angiotensin II receptor antagonist, were evaluated in healthy young and elderly male and female subjects. METHODS: Irbesartan was administered as two 25 mg capsules after a 10 h fast to 12 young men, 12 young women, 12 elderly men and 12 elderly women. Serial blood and urine sample were collected up to 96 h after the dose. Plasma and urine samples were analysed for irbesartan by h.p.l.c./fluorescence methods. RESULTS: No statistically significant gender effects were observed in peak plasma concentration (Cmax), area under the curve (AUC), and terminal elimination half-life (t1/2) of irbesartan. The geometric mean AUC and Cmax increased by about 43% and 49%, respectively, in the elderly subjects. Also the time to peak was significantly shorter in the elderly subjects compared with that observed in the young subjects. Renal clearance ofirbesartan was significantly reduced in the elderly females but this reduction is not likely to be of any clinical relevance since less than 3% of the administered dose of irbesartan is excreted unchanged in the urine. CONCLUSIONS: Although there was an effect of age on the pharmacokinetics of irbesartan, based on the safety and efficacy profile, no adjustment in irbesartan dosage is necessary with respect to age or gender.
AIMS: Single dose pharmacokinetics and safety of irbesartan, an angiotensin II receptor antagonist, were evaluated in healthy young and elderly male and female subjects. METHODS:Irbesartan was administered as two 25 mg capsules after a 10 h fast to 12 young men, 12 young women, 12 elderly men and 12 elderly women. Serial blood and urine sample were collected up to 96 h after the dose. Plasma and urine samples were analysed for irbesartan by h.p.l.c./fluorescence methods. RESULTS: No statistically significant gender effects were observed in peak plasma concentration (Cmax), area under the curve (AUC), and terminal elimination half-life (t1/2) of irbesartan. The geometric mean AUC and Cmax increased by about 43% and 49%, respectively, in the elderly subjects. Also the time to peak was significantly shorter in the elderly subjects compared with that observed in the young subjects. Renal clearance ofirbesartan was significantly reduced in the elderly females but this reduction is not likely to be of any clinical relevance since less than 3% of the administered dose of irbesartan is excreted unchanged in the urine. CONCLUSIONS: Although there was an effect of age on the pharmacokinetics of irbesartan, based on the safety and efficacy profile, no adjustment in irbesartan dosage is necessary with respect to age or gender.
Authors: J L Pool; R M Guthrie; T W Littlejohn; P Raskin; A M Shephard; M A Weber; M R Weir; T W Wilson; J Wright; K B Kassler-Taub; R A Reeves Journal: Am J Hypertens Date: 1998-04 Impact factor: 2.689
Authors: P B Timmermans; P C Wong; A T Chiu; W F Herblin; P Benfield; D J Carini; R J Lee; R R Wexler; J A Saye; R D Smith Journal: Pharmacol Rev Date: 1993-06 Impact factor: 25.468
Authors: V L Burt; P Whelton; E J Roccella; C Brown; J A Cutler; M Higgins; M J Horan; D Labarthe Journal: Hypertension Date: 1995-03 Impact factor: 10.190
Authors: C Cazaubon; J Gougat; F Bousquet; P Guiraudou; R Gayraud; C Lacour; A Roccon; G Galindo; G Barthelemy; B Gautret Journal: J Pharmacol Exp Ther Date: 1993-05 Impact factor: 4.030